On October 8, 2019 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported a poster presentation at the upcoming Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology, being held from October 15 – 17, 2019 in London, United Kingdom (Press release, Cellectar Biosciences, OCT 8, 2019, View Source [SID1234540943]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Details

Poster Title: Phospholipid lipid ether delivery vehicle shows specificity for a broad range of tumor cells and provides a novel and improved approach for targeted therapy.
Date: Tuesday, October 15, 2019, 9 a.m. – 5 p.m.
Location: Leonardo Royal Hotel Tower Bridge, London, UK

A copy of the presentation materials can be accessed on the Posters and Publications section of the Cellectar website once the presentation concludes.